{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:05Z","timestamp":1793135105726,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Department of Zunyi city","award":["HZ2020228"],"award-info":[{"award-number":["HZ2020228"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81860524"],"award-info":[{"award-number":["81860524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19897-5","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:19:55Z","timestamp":1760527195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["p53 and PD-1\/PD-L1 expression contribute to disease progression and are correlated to immune infiltrates in urothelial carcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Mingshun","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longmei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"19897_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024.CA. Cancer. J. Clin. 74, 12\u201349 (2024).","journal-title":"J. Clin."},{"key":"19897_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"WJ Alfred","year":"2024","unstructured":"Alfred, W. J. et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"19897_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat, E. et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 400, 1712\u20131721 (2022).","journal-title":"Lancet"},{"key":"19897_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41585-022-00620-2","volume":"19","author":"L Stone","year":"2022","unstructured":"Stone, L. Biomarkers for bladder cancer diagnosis, prognosis, monitoring and treatment. Nat. Rev. Urol. 19, 383 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"19897_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle, A. et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomized controlled trial. Lancet 395, 1268\u20131277 (2020).","journal-title":"Lancet"},{"key":"19897_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur. Urol. 84, 49\u201364 (2023).","journal-title":"Eur. Urol."},{"key":"19897_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/PAP.0000000000000421","volume":"31","author":"J Zhao","year":"2024","unstructured":"Zhao, J., Guo, C. C. & Rao, P. Contemporary issues in urothelial carcinoma of upper urinary tract. Adv. Anat. Pathol. 31, 80\u201387 (2024).","journal-title":"Adv. Anat. Pathol."},{"key":"19897_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal, R., Valderrama, B. P. & Bellmunt, J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat. Rev. Clin. Oncol. 21, 8\u201327 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"19897_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2021.04.012","volume":"39","author":"M Knowles","year":"2021","unstructured":"Knowles, M., Dyrskj\u00f8t, L., Heath, E. I., Bellmunt, J. & Siefker-Radtke, A. O. Metastatic urothelial carcinoma. Cancer Cell. 39, 583\u2013585 (2021).","journal-title":"Cancer Cell."},{"key":"19897_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/1873-3468.12061","volume":"590","author":"JH Park","year":"2016","unstructured":"Park, J. H., Zhuang, J., Li, J. & Hwang, P. M. p53 as guardian of the mitochondrial genome. FEBS Lett. 590, 924\u2013934 (2016).","journal-title":"FEBS Lett."},{"key":"19897_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/genes8020066","volume":"8","author":"Q Luo","year":"2017","unstructured":"Luo, Q., Beaver, J. M., Liu, Y. & Zhang, Z. Dynamics of p53: A master decider of cell fate. Genes (Basel). 8, 66 (2017).","journal-title":"Genes (Basel)"},{"key":"19897_CR12","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1158\/0008-5472.CAN-16-2832","volume":"77","author":"G Guo","year":"2017","unstructured":"Guo, G., Yu, M., Xiao, W., Cui, Y. & Celis E., & Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 77, 2292\u20132305 (2017).","journal-title":"Cancer Res."},{"key":"19897_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1158\/1055-9965.EPI-08-1037","volume":"18","author":"LM Morton","year":"2009","unstructured":"Morton, L. M. et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol. Biomarkers Prev. 18, 1259\u20131270 (2009).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"19897_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).","journal-title":"Nat. Med."},{"key":"19897_CR15","first-page":"829","volume":"4","author":"HB Grossman","year":"1998","unstructured":"Grossman, H. B. et al. p53 and RB expression predict progression in T1 bladder cancer. Clin. Cancer Res. 4, 829\u2013834 (1998).","journal-title":"Clin. Cancer Res."},{"key":"19897_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.juro.2017.06.086","volume":"198","author":"LM Krabbe","year":"2017","unstructured":"Krabbe, L. M. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J. Urol. 198, 1253\u20131262 (2017).","journal-title":"J. Urol."},{"key":"19897_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.30699\/ijp.2021.136330.2493","volume":"16","author":"M Ahadi","year":"2021","unstructured":"Ahadi, M. et al. Evaluation of P53 and CK20 immunohistochemical markers in comparison with morphologic findings in Low- and High-grade urothelial carcinomas. Iran. J. Pathol. 16, 297\u2013303 (2021).","journal-title":"Iran. J. Pathol."},{"key":"19897_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.clgc.2012.12.009","volume":"11","author":"JH Ku","year":"2013","unstructured":"Ku, J. H. et al. The role of p53 on survival of upper tract urothelial carcinoma: a systematic review and meta-analysis. Clin. Genitourin. Cancer. 11, 221\u2013228 (2013).","journal-title":"Clin. Genitourin. Cancer"},{"key":"19897_CR19","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.3892\/mmr.2015.3984","volume":"12","author":"D Tian","year":"2015","unstructured":"Tian, D. et al. Expression of brain-specific angiogenesis inhibitor-1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma. Mol. Med. Rep. 12, 4522\u20134529 (2015).","journal-title":"Mol. Med. Rep."},{"key":"19897_CR20","first-page":"197","volume":"14","author":"U Kumar","year":"2021","unstructured":"Kumar, U. et al. Immunoexpression of PD-L1 and PD-1 and its clinicopathological correlation in urothelial carcinomas. J. Lab. Physicians. 14, 197\u2013201 (2021).","journal-title":"J. Lab. Physicians"},{"key":"19897_CR21","doi-asserted-by":"publisher","first-page":"527385","DOI":"10.3389\/fonc.2020.527385","volume":"10","author":"B Kim","year":"2020","unstructured":"Kim, B., Lee, C., Kim, Y. A. & Moon, K. C. PD-L1 expression in Muscle-Invasive urinary bladder urothelial carcinoma according to Basal\/Squamous-Like phenotype. Front. Oncol. 10, 527385 (2020).","journal-title":"Front. Oncol."},{"key":"19897_CR22","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1002\/imt2.36","volume":"1","author":"W Shen","year":"2022","unstructured":"Shen, W. et al. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. IMeta 1, e36 (2022).","journal-title":"IMeta"},{"key":"19897_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. S. et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649\u2013658 (2017).","journal-title":"Neoplasia"},{"key":"19897_CR24","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"19897_CR25","doi-asserted-by":"publisher","first-page":"W214","DOI":"10.1093\/nar\/gkq537","volume":"38","author":"D Warde-Farley","year":"2010","unstructured":"Warde-Farley, D. et al. The genemania prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38, W214\u2013220 (2010).","journal-title":"Nucleic Acids Res."},{"key":"19897_CR26","doi-asserted-by":"publisher","first-page":"D808","DOI":"10.1093\/nar\/gks1094","volume":"41","author":"A Franceschini","year":"2013","unstructured":"Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808\u2013815 (2013).","journal-title":"Nucleic Acids Res."},{"key":"19897_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25\u201329. https:\/\/doi.org\/10.1038\/75556 (2000).","journal-title":"Nat. Genet."},{"key":"19897_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"19897_CR29","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"19897_CR30","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108\u2013110 (2017).","journal-title":"Cancer Res."},{"key":"19897_CR31","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru, B. et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics 35, 4200\u20134202 (2019).","journal-title":"Bioinformatics"},{"key":"19897_CR32","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1038\/s41598-021-84787-5","volume":"11","author":"\u00c1 Nagy","year":"2021","unstructured":"Nagy, \u00c1., Munk\u00e1csy, G. & Gy\u0151rffy, B. Pancancer survival analysis of cancer hallmark genes. Sci. Rep. 11, 6047 (2021).","journal-title":"Sci. Rep."},{"key":"19897_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.03.015","volume":"74","author":"G Sonpavde","year":"2018","unstructured":"Sonpavde, G., Dranitsaris, G. & Necchi, A. Improving the cost efficiency of PD-1\/PD-L1 inhibitors for advanced urothelial carcinoma: A major role for precision medicine?? Eur. Urol. 74, 63\u201365 (2018).","journal-title":"Eur. Urol."},{"key":"19897_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.eururo.2019.10.004","volume":"77","author":"AG de Lista","year":"2020","unstructured":"de Lista, A. G. et al. Clinical outcome after progressing to frontline and second-line Anti-PD-1\/PD-L1 in advanced urothelial cancer. Eur. Urol. 77, 269\u2013276 (2020).","journal-title":"Eur. Urol."},{"key":"19897_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/his.13225","volume":"71","author":"A Hodgson","year":"2017","unstructured":"Hodgson, A., Xu, B. & Downes, M. R. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71, 296\u2013304 (2017).","journal-title":"Histopathology"},{"key":"19897_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jcp-2021-207795","volume":"77","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. J. Clin. Pathol. 77, 61\u201367 (2023).","journal-title":"J. Clin. Pathol."},{"key":"19897_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.molimm.2020.05.010","volume":"124","author":"A Ariafar","year":"2020","unstructured":"Ariafar, A. et al. Clinical relevance and prognostic significance of PD-1\/PD-Ls in non-metastatic bladder cancer: A role for PD-L2. Mol. Immunol. 124, 35\u201341 (2020).","journal-title":"Mol. Immunol."},{"key":"19897_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui, L. & Chen, Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 368, 7\u201313 (2015).","journal-title":"Cancer Lett."},{"key":"19897_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang, T. et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal. Transduct. Target. Ther. 6, 72 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"19897_CR40","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3389\/fimmu.2018.02858","volume":"9","author":"D Namgaladze","year":"2018","unstructured":"Namgaladze, D. et al. Polarization of human macrophages by Interleukin-4 does not require ATP-citrate lyase. Front. Immunol. 9, 2858 (2018).","journal-title":"Front. Immunol."},{"key":"19897_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","volume":"6","author":"FO Martinez","year":"2014","unstructured":"Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).","journal-title":"F1000Prime Rep."},{"key":"19897_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14\u201320 (2014).","journal-title":"Immunity"},{"key":"19897_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.it.2012.11.001","volume":"34","author":"LB Ivashkiv","year":"2013","unstructured":"Ivashkiv, L. B. Epigenetic regulation of macrophage polarization and function. Trends Immunol. 34, 216\u2013223 (2013).","journal-title":"Trends Immunol."},{"key":"19897_CR44","doi-asserted-by":"publisher","first-page":"112575","DOI":"10.1016\/j.yexcr.2021.112575","volume":"402","author":"Y Wei","year":"2021","unstructured":"Wei, Y. et al. PD-L1 induces macrophage polarization toward the M2 phenotype via erk\/akt\/mtor. Exp. Cell. Res. 402, 112575 (2021).","journal-title":"Exp. Cell. Res."},{"key":"19897_CR45","doi-asserted-by":"publisher","first-page":"7157279","DOI":"10.3389\/fimmu.2021.715727","volume":"12","author":"M Roulleaux Dugage","year":"2021","unstructured":"Roulleaux Dugage, M., Jones, R. L., Trent, J., Champiat, S. & Dumont, S. Beyond the driver mutation: immunotherapies in Gastrointestinal stromal tumors. Front. Immunol. 12, 7157279 (2021).","journal-title":"Front. Immunol."},{"key":"19897_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol. Cancer. 22, 58 (2023).","journal-title":"Mol. Cancer"},{"key":"19897_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","volume":"67","author":"W Li","year":"2022","unstructured":"Li, W. et al. Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine Growth Factor. Rev. 67, 49\u201357 (2022).","journal-title":"Cytokine Growth Factor. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19897-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19897-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:05:45Z","timestamp":1760529945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19897-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19897"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19897-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36072"}}